Pain Franchise

About Bright Minds Biosciences

Bright Minds Biosciences is a mission-driven biotech focused on transforming treatment paradigms in CNS disorders through precision targeting of serotonin receptors. Founded in 2017, the company has rapidly advanced a proprietary platform to develop selective 5-HT2A and 5-HT2C agonists, deliberately engineered to avoid cardiotoxic 5-HT2B activity. Its strategy centers on de-risking clinical development through rigorous preclinical science and a deep, experienced leadership team. As a public company, it is positioned to leverage clinical milestones to address large, underserved markets in neurology and psychiatry.

Therapeutic Areas